Semaglutide orale nel trattamento dell’obesità: possibile alternativa alle terapie iniettive?
Il Diabete · 30.10.2026 · 38 (3)
DOI: 10.30682/ildia2603c ↗Kurz gefasst
Fachartikel in der Zeitschrift Il Diabete, online erschienen am 30.10.2026. Verfasst von Matteo Monami und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Once-daily oral semaglutide 25 mg is the first oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for the treatment of obesity (FDA, December 2025; EMA, July 2026). The molecule is the same as in the subcutaneous formulation; gastric absorption is enabled by the absorption enhancer SNAC. In the OASIS 4 trial (64 weeks), body weight decreased by 13.6% with oral semaglutide versus 2.2% with placebo. At the 25 mg dose, mean plasma exposure is comparable to that of subcutaneous semaglutide 2.4 mg; on this basis, the FDA extended to the tablet the indication for the reduction of major adverse cardiovascular events (MACE) demonstrated in SELECT. This extension is further supported by SOUL, in which lower oral doses (14 mg) reduced MACE by 14% in type 2 diabetes. The tolerability profile is that known for the class, mainly gastrointestinal, with discontinuations due to adverse events similar to placebo. In the United States, the tablet showed the fastest uptake ever observed for an anti-obesity medication, expanding the treated population rather than replacing injectable formulations. In Italy, the opinion of the Italian Medicines Agency (AIFA) is expected shortly.
Zitieren
APA
Monami, M., Ragghianti, B., & Silverii, G. A. (2026). Semaglutide orale nel trattamento dell’obesità: possibile alternativa alle terapie iniettive?. Il Diabete, 38(3). https://doi.org/10.30682/ildia2603c
Vancouver
Monami M, Ragghianti B, Silverii GA. Semaglutide orale nel trattamento dell’obesità: possibile alternativa alle terapie iniettive?. Il Diabete. 2026;38(3). doi:10.30682/ildia2603c
BibTeX
@article{Monami2026,
author = {Monami, Matteo and Ragghianti, Benedetta and Silverii, Giovanni Antonio},
title = {Semaglutide orale nel trattamento dell’obesità: possibile alternativa alle terapie iniettive?},
journal = {Il Diabete},
year = {2026},
volume = {38},
number = {3},
doi = {10.30682/ildia2603c}
}
EUVIMED